On November 16, 2012, the Illinois State tuberculosis (TB) program notified CDC's Division of Tuberculosis Elimination of a national shortage of 300 mg tablets of the antituberculosis medication isoniazid (INH). Subsequently, other state TB programs (e.g., California, Indiana, Maryland, New York, Virginia, and Wisconsin) reported difficulty obtaining INH 300 mg tablets. Other programs (e.g., San Diego) have experienced difficulties obtaining at least one of the commercially available anti-TB preparations containing the combination of rifampin and INH (IsonaRif [VersaPharm]).
Notes from the Field: National Shortage of Isoniazid 300 mg Tablets. JAMA. 2013;309(7):653. doi:10.1001/jama.2013.223
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: